US Patent 9,566,260: Claims, Scope, Expiration, Orange Book Status, and PNALD Patent Landscape
US Patent 9,566,260 protects selected clinical uses of fish-oil-derived omega-3 intravenous lipid emulsions for pediatric parenteral nutrition-associated liver disease, particularly in infants with short-bowel syndrome receiving total parenteral nutrition. It does not broadly claim fish oil, omega-3 fatty acids, or an injectable lipid composition. Its enforceable scope depends on satisfying multiple patient, nutrition, formulation, treatment-duration, and exclusion limitations.
The patent is assigned to Children’s Medical Center Corporation and is associated with the Omegaven clinical and regulatory program. The core commercial risk is concentrated in pediatric PNALD or PNAC treatment using an omega-3-only intravenous lipid emulsion, especially where the patient receives no plant-derived omega-6 fatty acids, phytosterols, or other parenteral lipid emulsion.
What does US Patent 9,566,260 protect?
The patent protects methods of treating liver disease associated with prolonged parenteral nutrition by administering a fish-oil-derived omega-3 lipid emulsion intravenously.
| Element |
Scope of US 9,566,260 |
| Patent number |
US 9,566,260 B2 |
| Title |
Treatment of parenteral nutrition-associated liver disease |
| Patent type |
Utility patent |
| Core technology |
Intravenous fish-oil-derived omega-3 lipid emulsion |
| Disease focus |
PNALD, PNAC, and specified liver disease |
| Patient population |
Children under 12; claims 2 and 3 focus on infants |
| Nutrition status |
Patient obtains nutritional requirements solely through TPN |
| Administration route |
Intravenous |
| Lipid restriction |
No other parenteral lipid emulsion during treatment under claim 1 |
| Fatty-acid restriction |
No plant-derived omega-6 fatty acids or plant-derived fatty acids |
| Phytosterol restriction |
No phytosterols under claims 2 and 3 |
| Treatment duration |
More than three weeks under claim 1; longer periods under dependent claims |
| Dose range |
0.2 to 3.0 g/kg/day; narrower range of 0.5 to 1.0 g/kg/day |
| Composition claim |
None apparent in the supplied claims |
| Method-of-use claim |
Yes |
The patent is therefore a patient-treatment and regimen patent rather than a standalone composition patent.
How many independent claims does US 9,566,260 have?
The supplied claim set has three independent claims: claims 1, 2, and 3.
Claim 1: Broadest general pediatric method
Claim 1 requires all of the following:
- A human patient with liver disease.
- Intravenous administration of a lipid emulsion.
- Nutritional requirements obtained solely through TPN.
- A lipid emulsion consisting essentially of an effective amount of fish oil rich in omega-3 fatty acids.
- No plant-derived omega-6 fatty acids.
- Treatment for more than three weeks.
- No other parenteral lipid emulsion during treatment.
- The patient is a child under 12.
Claim 1 is broader than claims 2 and 3 in disease and patient terminology because it does not expressly require short-bowel syndrome or infancy. It is narrower in other respects because it expressly requires treatment exceeding three weeks and excludes administration of another parenteral lipid emulsion.
Claim 2: Infant and short-bowel syndrome method
Claim 2 requires:
- A human infant.
- Short-bowel syndrome.
- PNALD.
- Sole reliance on TPN for nutritional requirements.
- Intravenous fish-oil-derived omega-3 fatty acids.
- No phytosterols or plant-derived fatty acids during treatment.
Unlike claim 1, claim 2 does not expressly include a minimum treatment duration. It also does not use the phrase “consists essentially of” in the same manner as claim 1, although it requires an intravenous lipid emulsion consisting of fish-oil-derived omega-3 fatty acids.
Claim 3: Replacement method
Claim 3 targets a treatment switch:
- The infant has short-bowel syndrome and PNALD.
- The infant receives nutrition solely through TPN.
- A plant-derived lipid emulsion is being administered.
- That plant-derived emulsion is replaced with an intravenous emulsion consisting of fish-oil-derived omega-3 fatty acids.
- The infant receives no phytosterols or plant-derived fatty acids during treatment.
Claim 3 creates a distinct infringement theory for switching from a soybean-based or other plant-derived parenteral lipid emulsion to an omega-3 fish-oil emulsion.
What limitations narrow the patent claims?
The claims contain several cumulative limitations that materially restrict their reach.
Sole total parenteral nutrition
The patient must obtain nutritional requirements solely through TPN. A patient receiving meaningful nutrition from enteral or oral intake may fall outside the literal scope of the independent claims, although claim 8 contemplates treatment continuing until adequate enteral nutrition becomes possible.
The phrase creates a factual issue involving the patient’s medical record, caloric intake, and the meaning of “nutritional requirements.” Trace oral or enteral intake may become relevant in a claim-construction or infringement dispute.
No plant-derived fatty acids or phytosterols
Claims 1 through 3 distinguish the claimed regimen from conventional soybean-containing emulsions. Soybean oil is a major source of omega-6 fatty acids and phytosterols in traditional parenteral lipid emulsions.
A product containing soybean oil, plant-derived fatty acids, or phytosterols may avoid literal infringement of claims 2 and 3 if the exclusion is present in the administered regimen. The analysis depends on whether the limitation applies to the emulsion, the patient’s entire treatment, or both.
No concurrent parenteral lipid emulsion
Claim 1 expressly requires that the patient not receive another parenteral lipid emulsion during treatment. Concurrent or alternating use of another lipid emulsion creates a potential noninfringement position for claim 1. Claims 2 and 3 do not use the same express “no other lipid emulsion” language, but they independently exclude specified plant-derived fatty acids and phytosterols.
Pediatric age limitation
Claim 1 requires a child under 12. Claim 11 narrows the patient to an infant. Claims 2 and 3 independently require an infant. Adult PNALD treatment is outside the supplied claim scope.
What do dependent claims 4 through 11 add?
| Claim |
Added limitation |
| 4 |
Treatment for more than six weeks |
| 5 |
Treatment for more than three months |
| 6 |
Liver disease is fatty liver disease |
| 7 |
Emulsifier selected from egg phosphatidylcholine, egg lecithin, DPPC, DPPE, or DOPC |
| 8 |
Treatment continues until adequate enteral nutrition is possible |
| 9 |
Dose of 0.2 to 3.0 g/kg/day |
| 10 |
Dose of 0.5 to 1.0 g/kg/day |
| 11 |
Child under 12 is an infant |
The dependent claims provide fallback positions if an independent claim is narrowed or invalidated. Claims 9 and 10 are particularly relevant to clinical protocols because they define dosing ranges commonly associated with intravenous fish-oil treatment.
Claim 7 is formulation-specific but remains a method claim. It does not independently claim an emulsion containing one of the listed emulsifiers.
What products and formulations are most exposed?
The principal product associated with the patent landscape is Omegaven, an intravenous fish-oil triglyceride emulsion marketed by Fresenius Kabi. FDA approved Omegaven in 2018 for use as a source of calories and fatty acids in pediatric patients with parenteral nutrition-associated cholestasis. The approval followed the clinical development of fish-oil lipid emulsions for PNALD and PNAC.[1]
Omegaven
Omegaven is the closest commercial product to the claimed treatment regimen because it is an intravenous fish-oil lipid emulsion used in pediatric patients with PN-associated cholestasis. Product-level use does not automatically establish infringement. The specific patient must meet the claim limitations, including TPN dependence, age, absence of plant-derived fatty acids or phytosterols, and, for claim 1, treatment exceeding three weeks.
Intralipid
Intralipid is a soybean-oil-based intravenous lipid emulsion. Its plant-derived fatty-acid and phytosterol content makes it materially different from the claimed omega-3-only treatment regimen. It is more relevant as the prior treatment being replaced under claim 3 than as a product practicing the claimed omega-3 method.
SMOFlipid
SMOFlipid contains a mixture of soybean oil, medium-chain triglycerides, olive oil, and fish oil. Its multi-oil formulation includes plant-derived lipid components. Use of SMOFlipid is less likely to satisfy claims requiring an emulsion consisting of fish-oil-derived omega-3 fatty acids and excluding plant-derived fatty acids or phytosterols.
Clinolipid and other mixed emulsions
Olive-oil/soybean-oil emulsions and other mixed lipid products present similar design-around characteristics. A manufacturer using a mixed-oil product can argue that the formulation does not satisfy the fish-oil-only or plant-fatty-acid exclusion limitations.
What is the Orange Book status of US 9,566,260?
Omegaven is an FDA-approved drug product regulated under NDA 210589. The Orange Book is the relevant FDA source for determining whether US 9,566,260 is listed against the approved product and whether an approved generic applicant would face a Paragraph IV certification.[2]
Patent listing must be evaluated separately from patent validity and infringement. An Orange Book listing does not establish that all approved uses infringe the patent. It identifies patents submitted by the NDA holder or authorized party as covering the drug, a method of using the drug, or both.
The commercial significance of US 9,566,260 depends on:
- Whether the patent is listed against Omegaven in the current Orange Book.
- Whether the approved labeling includes a use that falls within the claims.
- Whether an abbreviated new drug application applicant submits a Paragraph IV certification.
- Whether the NDA holder brings litigation within the statutory 45-day period.
- Whether the resulting litigation triggers a 30-month stay.
The FDA label identifies Omegaven’s pediatric PN-associated cholestasis indication and dosing information, making the patent’s method-of-use scope directly relevant to generic filing strategy.[1]
When does US 9,566,260 lose exclusivity?
US 9,566,260 issued on February 14, 2017. Its nominal patent term is tied to the earliest claimed priority date and is expected to extend into 2029, subject to the official USPTO term calculation, patent-term adjustment, terminal-disclaimer effects, and any applicable regulatory patent-term extension.[3]
The relevant commercial dates are:
| Event |
Date or status |
| Patent issued |
February 14, 2017 |
| FDA approval of Omegaven |
July 27, 2018 |
| Pediatric orphan-drug exclusivity |
FDA orphan exclusivity applied to the approved indication; expiration must be checked against the current FDA designation record |
| Patent expiration |
Nominally expected in 2029 based on the patent family’s earliest priority framework |
| Generic entry |
Potentially earlier through a successful Paragraph IV challenge, settlement, or noninfringing carve-out |
Omegaven’s regulatory exclusivity and patent exclusivity are separate. FDA orphan exclusivity can block approval of the same orphan indication even after a patent challenge succeeds, while a patent can continue after regulatory exclusivity expires.
Are there Paragraph IV challenges or patent litigation?
A complete current litigation conclusion requires matching the patent against PACER, ANDA litigation records, district-court dockets, and FDA Orange Book updates. The supplied claim text alone does not establish whether an ANDA applicant has filed a Paragraph IV certification or whether litigation is pending.
The principal litigation triggers would be:
- An ANDA applicant seeks approval for an omega-3 fish-oil intravenous emulsion.
- The applicant certifies that US 9,566,260 is invalid, unenforceable, or not infringed.
- The patent owner files suit under Hatch-Waxman.
- The FDA applies the resulting 30-month stay, subject to statutory exceptions.
A generic applicant could pursue several strategies:
- Challenge the written description or enablement of the pediatric treatment regimen.
- Challenge the meaning and support for “consists essentially of.”
- Argue that its label does not induce the claimed pediatric use.
- Use a label carve-out for the patented PNALD or PNAC indication.
- Administer a formulation containing plant-derived fatty acids or phytosterols.
- Target adults or patients receiving supplemental enteral nutrition.
- Argue that the treatment does not exceed three weeks or does not meet the claimed dose.
How strong is the patent estate for Omegaven?
The patent has meaningful but narrow blocking power.
Strengths
- It covers the clinical population most closely associated with Omegaven’s approved use.
- It claims treatment regimens rather than only a particular commercial formulation.
- It includes both initial administration and replacement of a plant-derived emulsion.
- The claims contain specific exclusions that correspond to the mechanistic distinction between fish-oil and soybean-based lipid emulsions.
- Dependent claims cover treatment duration, dose, and emulsifier selection.
Weaknesses
- The claims are highly fact-dependent.
- They require pediatric or infant patients, limiting the addressable market.
- They require sole TPN dependence in the independent claims.
- The fish-oil-only and no-plant-lipid limitations create formulation design-around opportunities.
- A label carve-out may reduce induced-infringement exposure.
- The patent does not, based on the supplied claims, block every intravenous omega-3 composition or every use of fish oil.
The estate is stronger against a product expressly labeled for pediatric PNALD or PNAC using a fish-oil-only emulsion in TPN-dependent infants than against a broad generic lipid-emulsion product with multiple indications.
What manufacturing and intellectual-property barriers exist?
Manufacturing barriers are moderate. Fish-oil intravenous emulsions require control of oxidation, lipid composition, particle size, sterility, emulsifier selection, and stability. These technical requirements may create regulatory and formulation-development barriers independent of US 9,566,260.
The patent itself does not appear to claim:
- Fish-oil extraction or purification.
- A specific triglyceride profile.
- A particular manufacturing process.
- Sterilization conditions.
- Container or oxygen-control systems.
- A standalone composition with defined percentages.
Those areas may be protected by separate composition, process, formulation, trade-secret, or regulatory exclusivity rights. A competitor that designs around US 9,566,260 may still face FDA comparability, stability, clinical, and manufacturing requirements.
How does US 9,566,260 compare with competing lipid-emulsion patent risks?
| Product or approach |
Relationship to US 9,566,260 |
Primary risk |
| Omegaven |
Closest commercial practice |
Direct method-of-use exposure in covered pediatric patients |
| Intralipid |
Plant-derived soybean emulsion |
More likely prior treatment under claim 3 than claimed final therapy |
| SMOFlipid |
Mixed-oil emulsion |
Potential design around plant-derived lipid limitations |
| Clinolipid |
Mixed olive/soybean formulation |
Reduced fit with fish-oil-only limitations |
| New fish-oil emulsion |
Potentially within claim scope |
Depends on label, patient population, formulation, and regimen |
| Adult omega-3 PN therapy |
Outside supplied pediatric limitations |
Lower direct risk under these claims |
| Fish-oil emulsion with enteral nutrition |
May avoid sole-TPN limitation |
Depends on the extent and role of enteral intake |
Key Takeaways
- US 9,566,260 is a narrow method-of-use patent for pediatric PNALD treatment with intravenous fish-oil-derived omega-3 lipid emulsions.
- Claims 1, 2, and 3 are independent claims.
- The most important limitations are pediatric age, sole TPN dependence, fish-oil omega-3 administration, and exclusion of plant-derived fatty acids, omega-6 fatty acids, phytosterols, or other lipid emulsions.
- Claim 3 specifically covers replacing a plant-derived lipid emulsion with a fish-oil-derived emulsion in an infant with short-bowel syndrome.
- Omegaven is the commercial product most closely aligned with the claimed treatment.
- Mixed-oil products such as SMOFlipid and soybean- or olive-oil-based products present potential design-around positions.
- The patent issued on February 14, 2017, and has a nominal term extending into 2029 based on its patent-family priority framework.
- FDA approval, orphan exclusivity, Orange Book listing, patent expiration, and Paragraph IV litigation are separate legal events.
- The principal generic-entry risks are an ANDA seeking the pediatric PNALD or PNAC indication, label-induced infringement, and a formulation that satisfies the omega-3-only limitations.
FAQs About US Patent 9,566,260
Does US 9,566,260 claim Omegaven itself?
No. The supplied claims are methods of treatment. They do not, on their face, claim Omegaven as a composition, container, manufacturing process, or standalone product.
Can a generic use a mixed fish-oil and soybean-oil emulsion without infringing?
A mixed formulation may have a noninfringement position because the claims exclude plant-derived fatty acids or require a fish-oil-derived omega-3 emulsion. The result depends on the precise formulation and treatment regimen.
Does treatment of an adult with Omegaven infringe these claims?
The supplied claims require a child under 12 or an infant. Adult treatment is outside the literal scope of those age limitations.
Does a patient receiving partial enteral nutrition fall within the claims?
The independent claims require the patient to obtain nutritional requirements solely through TPN. Enteral nutrition may therefore be material to the infringement analysis, particularly if it supplies a meaningful portion of nutritional requirements.
Is a biosimilar challenge relevant to US 9,566,260?
No. Omegaven is a conventional drug product, not a biologic subject to the biosimilar pathway. A competing applicant would generally use an ANDA, a 505(b)(2) application, or another applicable drug pathway rather than a biosimilar application.
References
-
U.S. Food and Drug Administration. (2018). Omegaven prescribing information, NDA 210589. FDA.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book. FDA.
-
United States Patent and Trademark Office. (2017). U.S. Patent No. 9,566,260 B2: Treatment of parenteral nutrition-associated liver disease. USPTO.
-
U.S. Food and Drug Administration. (1984). Drug Price Competition and Patent Term Restoration Act of 1984. FDA.
-
U.S. Food and Drug Administration. (2024). Orphan drug designations and approvals database. FDA.
